Monitor for potential overhang as selling stockholders may sell shares into the market after the registration becomes effective. The TCG Crossover Funds hold a combined 5,338,078 shares (approx. 9.8% of outstanding) and could gradually reduce positions. Watch for volume spikes and price pressure post-effectiveness.
VOR drugs
VOR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 28 $14.38entry
- T+1 · 7mo ago −1.88%α −1.87% · $14.11
- T+5 · 7mo ago +2.29%α +0.60% · $14.71
- T+20 · 6mo ago −1.95%α −7.42% · $14.10
- T+60 · 4mo ago +31.99%α +28.00% · $18.98
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vor Biopharma filed an S-3 registration statement to register 5,338,078 shares of common stock for resale by TCG Crossover Funds, issued in a March 2026 private placement at $14.05/share ($75M gross). The company will not receive any proceeds. This is a routine registration rights fulfillment and does not represent new equity issuance or capital raise.
Key Facts
- Registers 5,338,078 shares for resale by selling stockholders (TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P.)
- Shares were issued in a private placement on March 30, 2026 at $14.05 per share, gross proceeds ~$75M to the company
- Company will not receive any proceeds from this resale offering
- Stock closed at $13.81 on April 24, 2026; market cap ~$675M
- Shares outstanding as of April 22, 2026: 54,185,737
Financial Impact
No financial impact to the company; selling stockholders may realize proceeds up to ~$73.7M at current market price
Risk Factors
- Potential selling pressure from the registered shares could weigh on stock price
- No new capital raised for the company; reliance on existing cash and future financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-182106 |
| Document: d27587dexfilingfees.htm | 0001193125-26-182106 |
| Document: d27587dex51.htm | 0001193125-26-182106 |
| Document: d27587dex232.htm | 0001193125-26-182106 |
| Document: 0001193125-26-182106-index-headers.html | 0001193125-26-182106 |
| Document: 0001193125-26-182106-index.html | 0001193125-26-182106 |
| Document: 0001193125-26-182106.txt | 0001193125-26-182106 |
Track record
17 reports on VOR
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +70.35% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.97 Now $18.97 −0.00% settles Nov 18
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.32 to $19.42 Now $18.97 −1.81% ▲ +0.52% +0.88% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.66 to $19.88 Now $18.97 +1.66% ▲ +6.54% +6.23% vs SPY
- Oct 30, 202617d ago 424B5 Bearish 4/10 Entry $19.68 to $19.25 Now $18.97 +3.61% ▲ +2.19% +1.71% vs SPY
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $19.68 to $19.25 Now $18.97 −3.61% ▼ −2.19% −1.71% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $18.26 to $18.33 Now $18.97 +3.89% ▲ +0.38% −0.33% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $18.31 to $18.78 Now $18.97 +3.60% ▲ +2.57% +2.81% vs SPY
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $18.33 to $19.08 Now $18.97 +3.49% ▲ +4.09% +4.30% vs SPY
- Aug 11, 202613w ago Press Release Neutral 3/10 Entry $23.37 to $22.34 Now $18.97 −18.83% ▼ −4.41% −4.66% vs SPY
- Jul 9, 202618w ago 3 Neutral 2/10 Entry $19.14 to $18.03 Now $18.97 −0.89% ▼ −5.80% −5.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers